Devils Claw is NYAGs Current Supplement TargetDevils Claw is NYAGs Current Supplement Target
Eric Schneiderman’s office said the Harpagophytum zeyheri species of devil’s claw is less desirable than Harpagophytum procumbens. The natural products industry disagrees.
September 17, 2015
The New York Attorney General sent cease-and-desist letters to manufacturers of devil’s Claw supplements, saying DNA barcoding tests revealed that instead of containing the devil’s claw strain Harpagophytum procumbens, it contained the strain Harpagophytum zeyheri.
Schneiderman’s office said the zeyheri species is less desirable. The natural products industry disagrees.
Watch this INSIDER TV news desk to get the industry’s take.
You May Also Like
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
HerbalGram celebrates 40 years of bringing ancient herbal traditions back to life in AmericaSep 27, 2023
New science advances probiotics, milk fats and herbsSep 27, 2023